Transdermal estradiol in castrate and chemotherapy resistant prostate cancer

Medical Science Monitor

Volumn 18, Issue 4, 2012, Pages

  Stein, Mark ^a   Goodin, Susan ^a   Doyle Lindrud, Susan ^a,b   Silberberg, Jeffrey ^c   Kane, Michael ^c   Metzger, Dorinda ^a   Eddy, Simantini ^a   Shih, Weichung ^a,d   DiPaola, Robert S ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^d UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

Author keywords

Abiraterone; Estradiol; Prostate cancer; Testosterone

Indexed keywords

DOCETAXEL; ESTRADIOL; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; DRUG TOLERABILITY; HUMAN; MALE; PATIENT SAFETY; TREATMENT RESPONSE; TUMOR ABLATION;

EID: 84859528806     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.882626     Document Type: Article

References (26)

1. Huggins C, Hodges CV: The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. CA Cancer J Clin, 1972; 22(4): 232-40
2. Huggins C, Hodges CV: Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol, 2002; 168(1): 9-12
3. Byar DP: Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer, 1973; 32: 1126
4. Cassileth BR, Soloway MS, Vogelzang NJ et al: Patients' choice of treatment in stage D prostate cancer. Urology, 1989; 33: 57
5. Loblaw DA, Mendelson DS, Talcott JA et al: American Society of Clinical Oncology Recommendations for the Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer. J Clin Oncol, 2004; 22: 2927
6. Malkowicz SB: The role of diethylstilbestrol in the treatment of prostate cancer. Urology, 2001; 58: 108
7. Seidenfeld J, Samson DJ, Hasselblad V et al: Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med, 2000; 132: 566
8. Kitahara S, Umeda H, Yano M et al: Effects of intravenous administration of high dose-diethylstilbestrol diphosphate on serum hormonal levels in patients with hormone-refractory prostate cancer. Endocr J, 1999; 46: 659
9. Kitahara S, Yoshida K, Ishizaka K et al: Stronger suppression of serum testosterone and FSH levels by a synthetic estrogen than by castration or an LH-RH agonist. Endocr J, 1997; 44: 527
10. Shahinian VB, Kuo YF, Freeman JL et al: Increasing use of gonadotropin- releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer, 2005; 103: 1615
11. Weight CJ, Klein EA, Jones JS: Androgen deprivation falls as orchiectomy rates rise after changes in reimbursement in the U.S. Medicare population. Cancer, 2008; 112: 2195
12. Attard G, Cooper CS, de Bono JS: Steroid hormone receptors in prostate cancer: a hard habit to break? Cancer Cell, 2009; 16: 458
13. Harris WP, Mostaghel EA, Nelson PS et al: Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol, 2009; 6: 76
14. Bland LB, Garzotto M, DeLoughery TG et al: Phase II study of transdermal estradiol in androgen-independent prostate carcinoma. Cancer, 2005; 103: 717
15. Crawford ED, Flaig TW: Optimizing outcomes of advanced prostate cancer: drug sequencing and novel therapeutic approaches. Oncology, 2012; 26: 70
16. Scher HI, Beer TM, Higano CS et al: Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet, 2010; 375: 1437
17. Danila DC, Morris MJ, de Bono JS et al: Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel- treated castration-resistant prostate cancer. J Clin Oncol, 2010; 28: 1496
18. Ockrim JL, Lalani EN, Laniado ME et al: Transdermal estradiol therapy for advanced prostate cancer - forward to the past? J Urol, 2003; 169: 1735
19. Pravettoni A, Mornati O, Martini PG et al: Estrogen receptor beta (ERbeta) and inhibition of prostate cancer cell proliferation: studies on the possible mechanism of action in DU145 cells. Mol Cell Endocrinol, 2007; 263: 46
20. Bhattacharyya RS, Krishnan AV, Swami S et al: Fulvestrant (ICI 182,780) down-regulates androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells. Mol Cancer Ther, 2006; 5: 1539
21. Bonkhoff H, Berges R: The Evolving Role of Oestrogens and Their Receptors in the Development and Progression of Prostate Cancer. European Urology, 2009; 55: 533
22. Aro J, Haapiainen R, Rasi V et al: The effect of parenteral estrogen versus orchiectomy on blood coagulation and fibrinolysis in prostatic cancer patients. Eur Urol, 1990; 17: 161
23. Hedlund PO, Ala-Opas M, Brekkan E et al: Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer - Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Scand J Urol Nephrol, 2002; 36: 405
24. von Schoultz B, Carlstrom K, Collste L et al: Estrogen therapy and liver function - metabolic effects of oral and parenteral administration. Prostate, 1989; 14: 389
25. Kroon UB, Silfverstolpe G, Tengborn L: The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables. Thromb Haemost, 1994; 71: 420
26. Lycette JL, Bland LB, Garzotto M et al.: Parenteral estrogens for prostate cancer: can a new route of administration overcome old toxicities? Clin Genitourin Cancer, 2006; 5: 198